CELL ANALYSIS QUESTIONNAIRE for the FLOW CYTOMETRY CORE FACILITY.
(Includes terms and conditions of service, plus our acknowledgements policy)
Date:
Month: _____
Year: _____
Principal Investigator: _____
Phone Number: _____
Fax Number: _____
E-mail: _____
The purpose of this annual questionnaire is to determine the types of cells to be
analysed from your laboratory in the Flow Cytometry Core Facility and any related bio-safety
concerns. Please answer all of the questions below, date and return, either by e-mail
(HKGray@med.miami.edu), or print and return to the Flow Cytometry Facility, RMSB 3061:-
Section I.
Flow cytometric analysis (FACS Canto-II, LSR-II, LSR-Fortessa).
Cell types for analysis: _____
Species: _____
Cells from potentially infectious source?
Pathogen Risk Group (RG): _____
Yes _____
No _____
Biosafety level (BSL) 1, 2, 3, 4: _____
Note. All samples for analysis MUST be non-infectious and able to be handled under
BSL-1 conditions. Live infectious cells are not permitted to be analyzed on the FACS CantoII, LSR-II, or Fortessa. For analysis of potentially infectious materials under BSL-2
conditions, special bio-hazard facilities are available, using a FACS Aria. Please contact the
operator and/or laboratory director. Samples requiring BSL-3 or BSL-4 conditions CAN NOT
be handled under any circumstances in this facility.
Fixed cells from prior infectious source?
Please indicate fixative used: _____
Yes _____
No _____
Note. It is the P.I.’s responsibility to insure that the fixation used is suitable to render
the samples non-infectious. Validation may be required of the procedure. For more
information on protocols, please contact the operator and/or laboratory director.
For human samples, what is the source of cells (eg. volunteers, patients, blood bank, etc.)
and are patients tested for HIV, Hepatitis, HTLV, EBV, other pathogens? _____
For cell lines, were they transformed by, or carry, any known viral pathogens (e.g. HIV,
EBV, other)? _____
IF NOT TESTED, PLEASE INDICATE: _____
Institutional Review Board (IRB.) approval?
If yes, IRB. protocol number(s): _____
Date(s) of IBC. approvals: _____
Yes _____
No _____
Have copies of IBC. approval documents been submitted to the facility? Yes ____ No ____
If exempt, please explain and attach copies of the exemption documents:-
U.M. Office of Environmental Health and Safety (Biosafety Officer) approval?
Yes _____
No _____
Analysis of genetically manipulated cells.
Are the cells to be analysed genetically engineered or manipulated? Yes _____ No_____
If yes, is a gene therapy virus, eg. adenovirus, retrovirus, lentivirus, herpesvirus, etc.,
employed? Please indicate and specify:Viral vector: _____
(e.g., LentiMax, or other)
Is a helper virus used also? _____
If so, which? _____
Nature of insert(s) (oncogenes?): _____
Replication incompetent (specify): _____
Capacity of virus to infect human cells: _____
Are transduced cells passaged at least 3 times prior to analysis?
Yes _____ No _____
Are cells transfected with plasmids? _____
Nature of inserts? _____
BSL level: 1, 2, 3, 4: _____
(Note: No materials rated BSL-3 or BSL-4 can be handled in this facility)
Institutional Review Board (IRB.) approval?
If yes, IRB. protocol number(s): _____
Date(s) of IBC. approvals: _____
Yes _____
No _____
Have copies of IBC. approval documents been submitted to the facility? Yes ____ No ____
If exempt, please explain and attach copies of the exemption documents:-
U.M. Office of Environmental Health and Safety (Biosafety Officer) approval?
Yes _____
No _____
Note. Genetically manipulated cells MUST be rendered compatible with BSL-1 handling, by
appropriate fixation prior to analysis on the FACS Canto-II, LSR-II and Fortessa. Analysis of
BSL-2 samples is available under bio-hazard conditions only on the FACS Aria. Please contact
the operator and/or laboratory director for more information.
Section II.
Flow cytometric cell sorting (FACS Aria, MoFlo XDP).
Cell types for sorting: _____
Species: _____
Cells from potentially infectious source?
Pathogen Risk Group (RG): _____
Yes _____
No _____
BSL 1, 2, 3, 4: _____
Note. Samples for cell sorting can be handled under either BSL-1 or BSL-2 conditions only.
Samples requiring BSL-3 or BSL-4 conditions CAN NOT be handled under any
circumstances in this facility. For BSL-2 sorts, please contact the operator and/or laboratory
director for more information.
Fixed cells from a prior infectious source?
Please indicate any fixative used: _____
Yes _____
No _____
Note. It is the P.I.’s responsibility to insure that any fixation used is suitable to render the
samples non-infectious. Validation may be required of the procedure. For more information
on protocols, please contact the operator and/or laboratory director.
For human samples, what is the source of cells (eg. volunteers, patients, blood bank, etc.)
and are patients tested for HIV, Hepatitis, HTLV, EBV, other pathogens? _____
For cell lines, were they transformed by, or carry, any known viral pathogens (e.g. HIV,
EBV, other)? _____
IF NOT TESTED, PLEASE INDICATE: _____
Institutional Review Board (IRB.) approval?
If yes, IRB. protocol number(s): _____
Date(s) of IBC. approvals: _____
Yes _____
No _____
Have copies of IBC. approval documents been submitted to the facility? Yes ____ No ____
If exempt, please explain and attach copies of the exemption documents:-
U.M. Office of Environmental Health and Safety (Biosafety Officer) approval?
Yes _____
No _____
Sorting of genetically manipulated cells.
Are the cells to be sorted genetically engineered or manipulated?
Yes _____ No _____
If yes, is a gene therapy virus, eg. adenovirus, retrovirus, lentivirus, herpesvirus, etc.,
employed? Please indicate and specify:Viral vector: _____
(e.g., LentiMax, or other)
Is a helper virus used also? _____
If so, which? _____
Nature of insert(s) (oncogenes?): _____
Replication incompetent (specify): _____
Capacity of virus to infect human cells: _____
Are transduced cells passaged at least 3 times prior to analysis? Yes ______ No _____
Are cells transfected with plasmids? _____ Nature of inserts? _____
BSL level: 1, 2, 3, 4: _____
(Note: No materials rated BSL-3 or BSL-4 can be handled in this facility)
Institutional Review Board (IRB.) approval?
If yes, IRB. protocol number(s): _____
Date(s) of IBC. approvals: _____
Yes _____
No _____
Have copies of IBC. approval documents been submitted to the facility? Yes ____ No ____
If exempt, please explain and attach copies of the exemption documents:-
U.M. Office of Environmental Health and Safety (Biosafety Officer) approval?
Yes _____
No _____
Any other potential bio-hazard or safety concerns for cell sorting? Yes _____ No _____
Note that cell sorting generates extensive aerosols, so pathogens with aerosol routes of
transmission are of particular concern.
If yes, please explain: _____
Note. Cell sorting of genetically manipulated cells under BSL-2 conditions is available. Please
contact the operator and/or laboratory director for more information. Please note that, for
each sort, a separate cell sorting form is required. This form does not replace the required
individual cell sorting form, to be submitted in advance of any proposed sort.
Terms and conditions of service.
•
It is the vital responsibility of all users of the analysis instruments always to ensure
that both the Sheath and Waste fluid levels have been checked. If any of the
analysers are run dry and, as a consequence, their flow cells are damaged again,
then the user’s P.I. may receive a substantial bill for the subsequent repairs, because
these particular failures are caused by operator abuse of the instruments, thus not
covered under our maintenance contract. Signing this form also confirms your
group’s acknowledgement and acceptance of these conditions.
•
Please understand that our facility here is not certified for clinical work and thus,
we are not allowed to perform any clinical analysis and that none of our data ever is
to be reported for clinical purposes. Thus, all of the data which we are generating is
limited to and exclusively for research purposes only, None of our data is not meant
in any way, shape, or form to be used for any clinical evaluation and/or treatment of
patients.
•
Please also ensure that all of your data always is removed from the instruments’
computers after each and every run. We do delete excess data files monthly, to
conserve the computer work-stations’ disk space and the facility can not be held
responsible for any data so lost.
•
All groups must deposit a monthly IDR. with the facility, otherwise their access to
the on-line instrument reservation system will be locked. This open IDR. will be
used at the end of the month to pay the invoice generated from the SRS. accounting
system for the instrument time reserved. This IDR. is not a “blank cheque” and the
facility always is willing to discuss any questions over charges with the user, before
any such payments are made.
•
The facility requires a full liability waiver from all users, in relation to any and all
data, results and analyses generated, as well as to all actual physical samples
brought to the facility, plus to all experimental data acquisition and analysis
protocols. Caveat emptor.
Acknowledgements policy.
N.B. Please ensure that you always keep the facility up-dated with all new publications,
made using any of our instruments and services.
• Acknowledgement in publications:All work performed in the Flow Cytometry Core Facility should be acknowledged in
scholarly reports, presentations, posters, papers, and publications.
• Why acknowledge us:Proper acknowledgment provides a visible measure of the impact of the Sylvester
Comprehensive Cancer Center’s Core Facilities Shared Resources and is thus essential for
our continued funding and support.
• When to acknowledge:• Any time the Flow Cytometry Core Facility provides services that support your research.
• If a staff member has made a significant intellectual contribution beyond routine sample
analysis, please consider co‐authorship.
• Where to acknowledge:• Scholarly reports.
• Presentations.
• Posters.
• Papers.
• Publications.
•
Format for the acknowledgment:-
Please acknowledge us using the following suggested format:“We would like to acknowledge the skilled assistance of the Flow Cytometry Core
Facility of the Sylvester Comprehensive Cancer Center at the University of Miami, Miller
School of Medicine, for the provision of sophisticated fluorescence analysis and cell sorting
services”.
Formal agreement.
Signature of P.I. ___________________________________ Date: ______________________
Note. Safe use of the Flow Cytometry Core Facility relies upon co-operation between the staff
and investigators who use the facility. Thank you for helping in this endeavor. As cell types
and/or bio-hazard information change, prior to the next annual survey, this form will be updated accordingly and appropriate consultation with Flow Cytometry Core Facility staff will
occur in a timely manner, in order to ensure a maximum level of safety and efficiency.